Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.66 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.52 |
| ▸ | HRH1 | P35367 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | KIT | P10721 | 1/20 | 0.51 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.51 |
| ▸ | FLT3 | P36888 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.50 |
| ▸ | SORD | Q00796 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | GBA1 | P04062 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17005627 | 0.87 | HRH4 (0.62) | HRH4PTK2HTTLMNASMN1; SMN2 | |
| SCHEMBL12844776 | 0.80 | HRH4 (1.00) | HRH4PTK2HTTLMNASMN1; SMN2 | |
| SCHEMBL8134047 | 0.78 | HRH4 (0.64) | HRH4LMNADRD2DRD3SLC2A1 | |
| SCHEMBL11188038 | 0.78 | LMNA (0.65) | HTTLMNASMN1; SMN2ALDH1A1SLC2A1 | |
| SCHEMBL31502028 | 0.77 | ENPP1 (0.61) | HRH4PTK2HTTLMNASMN1; SMN2 | |
| SCHEMBL20814058 | 0.77 | ENPP1 (0.61) | HRH4PTK2HTTLMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL11393397 | 0.77 | LMNA (0.63) | LMNASMN1; SMN2ALDH1A1SLC2A1GBA1 | |
| SCHEMBL29230285 | 0.76 | JAK3 (0.59) | KIT | |
| SCHEMBL29230280 | 0.76 | LMNA (0.57) | HRH4PTK2HTTLMNASMN1; SMN2 | |
| SCHEMBL2079895 | 0.76 | HRH4 (0.61) | HRH4PTK2HTTLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309133-B2 | Nanoparticulate quinazoline derivative formulations | ALKERMES PHARMA IRELAND LIMITED (IE) | 2012-11-13 | — | — | US | disclosed |
| EP-1871345-B1 | NANOPARTICULATE ERLOTINIB FORMULATIONS | ELAN PHARMA INT LTD (IE) | 2012-08-01 | — | — | EP | disclosed |
| EP-1871345-A1 | NANOPARTICULATE QUINAZOLINE DERIVATIVE FORMULATIONS | Elan Pharma International Limited (IE) | 2008-01-02 | — | — | EP | disclosed |
| US-20060246142-A1 | Nanoparticulate quinazoline derivative formulations | ELAN PHARMA INTERNATIONAL, LIMITED | 2006-11-02 | — | — | US | disclosed |
| WO-2006110811-A1 | NANOPARTICULATE QUINAZOLINE DERIVATIVE FORMULATIONS | ELAN PHARMA INTERNATIONAL LIMITED (IE) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060246142-A1 | Nanoparticulate quinazoline derivative formulations | KRAS, NRAS, ABL1 | HRH4 325/4885PTK2 1185/4885HTT 619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.